Glytas M 30mg/500mg Tablet ER is a combination oral antidiabetic medication containing Gliclazide 30mg and Metformin 500mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet and exercise alone. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The extended-release formulation ensures a gradual release of active ingredients, promoting sustained plasma concentrations, reducing dosing frequency, and enhancing patient compliance. Glytas M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is primarily associated with the sulfonylurea component. Regular monitoring of blood glucose levels, renal function, and periodic assessment of hematologic parameters are recommended during therapy to optimize efficacy and safety.